Universe Pharmaceuticals Inc. (UPC)

Nasdaq: UPC · Pharmaceutical Preparations · Ji'An, Jiangxi, CN · filing with the SEC since 2020

Grade6.0

◀ Past 6.0● Present 6.7▶ Future 5.1

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in September.

Income statement, by fiscal year, newest first
Fiscal year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Report filed	Jan 29, 2026	Apr 29, 2025	Jan 30, 2024	Feb 10, 2023	Jan 31, 2022	·	·
Revenue	17,858,732,000	23,024,458,000^r	32,308,735,000^r	40,143,151	47,982,031	30,703,960	33,229,316
For insurers
Net investment income	·	·	31,072	38,588	30,827	21,820	26,741
Cost of revenue	11,557,563,000	16,952,556,000^r	21,993,601,000^r	18,251,815	22,655,854	16,610,140	19,821,831
Gross profit	6,301,169,000	6,071,902,000^r	10,315,134,000^r	21,891,336	25,326,177	14,093,820	13,407,485
Research and development	671,761,000	3,031,115,000^r	4,858,548,000^r	7,644,375	5,465,662	583,125	618,437
General and administrative	3,747,705,000	2,889,652,000^r	2,638,984,000^r	2,183,270^r	3,296,844	1,703,424	1,457,393
Total operating expenses	9,217,088,000	14,091,742,000^r	14,281,235,000^r	28,910,780^r	11,736,037	3,842,095	3,654,656
Operating income	-2,915,919,000	-8,019,840,000^r	-3,966,101,000^r	-7,019,444^r	13,590,140	10,251,725	9,752,829
Interest expense	289,385,000	304,516,000	190,184,000^r	162,400	101,604	123,760	129,268
Interest and investment income	·	·	38,530	-470,477	239,549	·	·
Share of profit of equity-method investments	65,058,000	31,942,000^r	31,072,000^r	38,588	30,827	21,820	26,741
Other income (expense), net	-108,044,000	145,476,000^r	-235,614,000^r	48,940^r	88,338	-151,292	-99,767
Total non-operating income (expense)	-756,136,000	-100,754,000^r	-361,330,000^r	-74,872	·	·	·
Income before income taxes	-3,672,055,000	-8,120,594,000^r	-4,327,431,000^r	-7,094,316^r	13,678,478	10,100,433	9,653,062
Income tax expense	·	606,704,000^r	2,253,593,000^r	815,322^r	2,358,526	2,542,211	2,101,597
Net income including non-controlling interests	·	·	·	-8,736,566	11,319,952	7,558,222	7,551,465
Net income	-3,672,055,000	-8,727,298,000^r	-6,581,024,000^r	-7,909,638^r	11,319,952	7,558,222	·
Earnings per share, basic	-8.06	-626.96	-1,089.21^r	-1,309.11^r	3.58^r	2.82^b	·
Earnings per share, diluted	-8.06	-626.96	-1,089.21^r	-1,309.11^r	3.58^r	2.82^b	·
Earnings per share, basic and diluted	·	·	·	·	3.60^b	2.82^b	2.82^b
Weighted average shares, basic	455,871	13,920	6,042^r	6,042^r	3,163,470^r	2,666,667^b	·
Weighted average shares, diluted	455,871	13,920	6,042^r	6,042^r	3,163,470^r	2,666,667^b	·
Weighted average shares, basic and diluted	·	·	·	·	3,163,470^b	2,666,667^b	2,666,667^b

As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-6 reverse split.A dot is a line not tagged for that period. ^r restated by the company in a later report; ^b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.

What each line is, and the XBRL concept behind it

Revenue what customers paid for what it soldus-gaap:Revenues

Net investment income what its investments earnedus-gaap:NetInvestmentIncome

Cost of revenue what it cost to make or buy what it soldus-gaap:CostOfRevenue

Gross profit revenue less the cost of what it soldus-gaap:GrossProfit

Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense

General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense

Total operating expenses the running costs togetherus-gaap:OperatingExpenses

Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss

Interest expense what its borrowing costus-gaap:InterestExpense

Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeNet

Share of profit of equity-method investments its share of companies it partly ownsus-gaap:IncomeLossFromEquityMethodInvestments

Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense

Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense

Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit

Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss

Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss

Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic

Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted

Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted

Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic

Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted

SI Assistanton UPC · research, not advice